论文部分内容阅读
作者在过去研究中证明,肺结核患者采取ZHRZS/4H_2R_2的6个月化疗方案,经30个月随访未见有复发病例。为了评价SM在此方案中的作用,对213例新发现的菌阳肺结核患者随机分成两组:一组为无SM组(ZHRZ/4H_2R_2),另一组为SM组(ZHRSZ/4H_2R_2)。分组时注意到每一方案中患者的性别、年龄、体重、INH乙酰化率、治疗前结核菌的生长情况和X线病变范围方面的比较。213例患者中172例(81％)完成治疗,即无SM组为116/135占86％,SM组为56/78占72％(X~2连续矫正=5.47,P=0.019)。未完成疗程者主
The authors in previous studies demonstrated that patients with tuberculosis treated with ZHRZS / 4H_2R_2 for 6 months had no recurrence after 30 months of follow-up. To evaluate the role of SM in this regimen, 213 newly diagnosed bacillary positive pulmonary tuberculosis patients were randomly divided into two groups: one with no SM (ZHRZ / 4H_2R_2) and the other with SM (ZHRSZ / 4H_2R_2). Grouping was noted for each patient’s gender, age, weight, INH acetylation rate, pre-treatment TB growth and X-ray lesion comparisons. Of the 213 patients, 172 (81%) completed the treatment, with 86% of 116/135 in the SM group and 72% in 56/78 of the SM group (X = 2 = 5.47, P = 0.019). Unfinished course of treatment